Clinical trial
WT1 for the Detection of Minimal Residual Disease
NCT00179829 · Ann & Robert H Lurie Children's Hospital of Chicago, Other · Completed
Key facts
| NCT number | NCT00179829 |
|---|---|
| Title | WT1 for the Detection of Minimal Residual Disease |
| Official title | Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR |
| Lead sponsor | Ann & Robert H Lurie Children's Hospital of Chicago, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Cancer |
| Intervention type | Procedure |
| Interventions | WT 1 Testing |
| Enrollment | 50 |
| Start date | Feb 1, 1999 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Feb 4, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: